Molecular Sensing

Founded in 2007 and based in Nashville, Tennessee, Molecular Sensing, Inc. (MSI) is a pioneering medical organization dedicated to advancing drug discovery. The company's core mission is to revolutionize biophysical characterization through innovative technology. MSI offers Back-Scattering Interferometry (BSI), the world’s first label-free, conformation-sensitive, free-solution assay technology. This breakthrough allows for true binding characterization of small molecule interactions with complex drug targets, including crude membrane protein preparations, in native-like environments.

Molecular Sensing has attracted notable investors and affiliations within the biotech and pharmaceutical industries due to its groundbreaking technology. The company’s key achievements include the successful commercialization of BSI, which has significantly impacted the drug discovery process by providing more accurate and efficient methods for characterizing molecular interactions. MSI's technology has the potential to streamline the development of new therapeutics, thereby enhancing the overall impact on medical research and patient outcomes.